SCHEMBL121041

SCHEMBL121041

C1=CN=NSC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL234916 0.67
SCHEMBL18321327 0.58
SCHEMBL2691891 0.58
SCHEMBL22230554 0.58
SCHEMBL84537 0.55
SCHEMBL84535 0.55
Hydrochloric Acid SCHEMBL27340903 0.55
SCHEMBL4449549 0.53
Hydrochloric Acid SCHEMBL1366326 0.53
SCHEMBL5050148 0.53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 979 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114555763-A Additives for reducing friction and wear 马来西亚国家石油公司 2022-05-27 CN claimed
CN-113861128-A Polymerizable compound and optically anisotropic body 江苏创拓新材料有限公司 2021-12-31 CN claimed
US-20190071485-A1 Novel Substitution Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System INTREXON CORP (US) 2019-03-07 US claimed
US-10087231-B2 Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system INTREXON CORPORATION (US) 2018-10-02 US claimed
US-20170015728-A1 Novel Substitution Mutant Receptors and Their Use in an Ecdysone Receptor-Based Inducible Gene Expression System INTREXON CORPORATION (US) 2017-01-19 US claimed
EP-1852420-B1 Indole compounds for treating respiratory disorders ONO PHARMACEUTICAL CO (JP) 2012-10-17 EP claimed
EP-1534738-B1 NOVEL SUBSTITUTION MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM INTREXON CORP (US) 2012-06-20 EP claimed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US claimed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US claimed
US-7402580-B2 Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-07-22 US claimed
US-20020187972-A1 Methods for modulating expression of exogenous genes in mammalian systems THE SALK INSTITUTE OF BIOLOGICAL STUDIES 2002-12-12 US claimed
WO-2002066615-A2 NOVEL SUBSTITUTION MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM RHEOGENE, INC. (US) 2002-08-29 WO claimed
US-20020032325-A1 4-amino-3-mercapto-1,2,4-triazoles HEINDEL NED D (US) 2002-03-14 US claimed
US-6333318-B1 USED IN THERAPY; FOR DELIVERING RECOMBINANT PROTEINS INTO A VARIETY OF CELLS WITHIN A PATIENT THE SALK INSTITUTE FOR BIOLOGICAL STUDIES 2001-12-25 US claimed
EP-1109551-A1 4-AMINO-3-MERCAPTO-1,2,4-TRIAZOLES Competitive Technologies, Inc. (US) 2001-06-27 EP claimed
EP-1076569-A1 FORMULATIONS USEFUL FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2001-02-21 EP claimed
EP-1054877-A1 NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS Du Pont Pharmaceuticals Company (US) 2000-11-29 EP claimed
WO-2000010564-A1 4-AMINO-3-MERCAPTO-1,2,4-TRIAZOLES COMPETITIVE TECHNOLOGIES, INC. (US) 2000-03-02 WO claimed
WO-1999058155-A1 FORMULATIONS USEFUL FOR MODULATING EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS, AND PRODUCTS RELATED THERETO THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1999-11-18 WO claimed
WO-1999041246-A1 NOVEL CYCLIC SULFONAMIDE DERIVATIVES AS METALLOPROTEINASE INHIBITORS DU PONT PHARMACEUTICALS COMPANY (US) 1999-08-19 WO claimed